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ABSTRACT 
The purpose of this thesis was to investigate new possible compounds that can be used to treat 
orthopedic implant infections caused by bacterial pathogens. Current treatment includes the use 
of antibiotics and the DAIR procedure, which stands for debridement, antibiotic therapy, 
irrigation, and retention. However, antibiotics are becoming less effective as a treatment due to 
bacteria gaining antibiotic resistance. Two bacterial species involved in orthopedic implant 
infections are P. aeruginosa and S. aureus. This thesis investigated cerium oxide nanoparticles 
and L. fermentum, a beneficial bacterium, as possible treatments to stop bacterial growth and the 
formation of biofilm. This was done by using the Kirby-Bauer disk diffusion method with P. 
aeruginosa and S. aureus. An XTT assay, a viability assay, was also performed on RAW 
macrophages to determine how these compounds affect human immune cells. Dextran-coated, 
50/50, and 70/30 Ce4+/Ce3+ CNP (cerium oxide nanoparticles) at 1, 10, 20, 100, 500, and 800 
µg/mL were investigated. These kinds of CNP were investigated to determine which type of 
CNP and at what concentration was most effective. The results show significant reductions (p-
value ≤ 0.05) in infection totals for various treatments, such as 10 µg/mL 50/50 CNP (cerium 
oxide nanoparticles). This study adds to the field of research in investigating new treatments for 
orthopedic implant infections. 
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INTRODUCTION 
 
Orthopedic implants have allowed people to regain function in parts of their body that 
have ceased working on their own or have undergone trauma. However, these implants are 
susceptible to infection, also known as prosthetic joint infection. As the elderly population 
grows, more and more people will require surgery to implant an orthopedic device. It is projected 
that by 2050, the number of total knee arthroplasties alone will exceed one million cases per year 
[1]. Orthopedic implant infections are not common, but when they do occur, they are very 
expensive. The average cost of a readmission for total knee arthroplasty due to complications 
was found to be $27,979 [2]. It is always better to prevent a disease than to treat it. Risk factors 
that make a patient prone to developing an orthopedic implant infection include a blood 
transfusion after the operation, and the length and location of the surgery. Patients are also more 
at risk if they have a chronic illness, take certain medications that interfere with wound healing, 
and/or have an infection present in the body at the time of the surgery [3]. Orthopedic implant 
infections can be divided into 3 different stages: early-onset (within 3 months of surgery), 
delayed-onset (between 3 months and 1 year after surgery), and late-onset (1-2+ years after 
surgery). The stage of the disease has an effect on the bacteria present. For example, 
polymicrobial infections tend to be present in early stages of infection, while coagulase-negative 
staphylococci are more commonly seen in the delayed stage [3]. Some pathogenic organisms are 
difficult to culture, which makes it difficult for orthopedic implant infections to be detected and 
diagnosed [3]. Criteria for diagnosing orthopedic implant infections include the presence of a 
sinus tract that is in contact with the prosthetic unit, the presence of pus around the prosthesis, 
and elevated counts of certain immune cells and proteins. However, the diagnostic criteria differs 
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by the organization, which is another difficulty with establishing diagnosis of an orthopedic 
implant infection [3]. Khosravi et al found that the three most common bacteria found in 
orthopedic implant infections are S. aureus, K. ozaenae, and P. aeruginosa [4]. S. aureus 
accounts for 34% of orthopedic implant infections, while Pseudomonas accounts for 8%, which 
includes P. aeruginosa [5]. S. aureus and P. aeruginosa were chosen for this project because S. 
aureus represents a Gram-positive bacterium, while P. aeruginosa represents a Gram-negative 
bacterium.  
Biofilms are formed when cells become attached to a surface, and have genetic 
expression and produce products that differ from planktonic cells of the same species [6]. Due to 
different conditions present in a biofilm, bacteria in different parts of the biofilm exhibit gene 
expression that differs from bacteria in other sections of the biofilm. S. aureus biofilms exhibit 4 
different sections [7]. The most active sections are those at the surface (due to contact with 
oxygen) and those at the bottom (due to contact with nutrients). Biofilm is composed of the 
bacterial cells. Biofilm formation occurs in four stages: attachment of the bacteria to the surface, 
the formation of a microcolony, maturation of the biofilm, and dispersal to a new area [8]. 
Biofilms are beneficial for bacteria and when formed, are difficult to treat clinically. They allow 
the bacteria to evade host defenses due to their slowed growth and lowered metabolism. Biofilms 
also serve as a barrier to antimicrobial compounds by preventing them from reaching lower 
levels of the biofilm [7]. Biofilms also allow infections to spread when single cells or sections of 
the biofilm detach and migrate to other parts of the body. The gene products of the intercellular 
adhesion (ica) locus are necessary for biofilm to form. These gene products are necessary to form 
polysaccharide intercellular adhesin. In the case of S. aureus, this locus is regulated by a 
Staphylococcus specific regulator and environmental factors, such as temperature and glucose. 
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Some strains of Staphylococcus are able to form biofilms without the products of the ica locus. 
Extracellular DNA also plays a role in biofilm formation. It is necessary for cells to lyse and for 
DNA to be released in order for the biofilm to form properly. In Staphylococcus species, 
staphylococcal accessory regulator (sarA) functions in cells attaching to a surface and forming a 
biofilm, while accessory gene regulator (agr) plays a role in seeding dispersal and fights against 
the immune system of the host organism by increasing virulence of the biofilm organism [7]. 
Iron is necessary for the formation of biofilm of P. aeruginosa. When lactoferrin, an iron 
chelator, is present, P. aeruginosa is not able to form thick biofilms. A lack of iron was 
demonstrated to prevent biofilm formation from moving past stage 2, which is the formation of a 
microcolony [9]. Iron also plays an important role in biofilm formation in S. aureus [10]. When 
S. aureus is in its planktonic state, macrophages cause inflammation. However, when S. aureus 
forms a biofilm, macrophages are inhibited and the amount of cell death increases [11]. “Race 
for the surface” is a term often used when discussing infections related to implanted materials. 
This term refers to the “race” between bacterial adhesion and subsequent biofilm formation, and 
integration of host tissue. The side that reaches the implant first colonizes the implant and makes 
it less likely for the other side to gain a foothold on the implant surface [12].  
Macrophages play a central role in inflammation. When potentially harmful microbes 
enter the body, PRRs on macrophages recognize PAMPs on the microorganisms. This leads to 
the release of pro-inflammatory cytokines, such as IL-6. These pro-inflammatory cytokines 
regulate the inflammatory response [13]. Acute inflammation is positive because it localizes the 
infection and minimizes widespread injury. However, chronic inflammation is harmful to the 
body. The inflammation response is mediated through the JAK-STAT, MAPK, and NF- κB 
pathways [14]. An excess of reactive oxygen species has been linked to chronic inflammation 
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[15]. Reactive oxygen species also affect osteoclasts, which are responsible for breaking down 
bone. Hydrogen peroxide, an example of a reactive oxygen species, has been shown to be vital 
for osteoclast activity [16]. Reactive oxygen species play a role in regulating stem cell 
differentiation and self-renewal. Reactive oxygen species influence the fate of stem cells by 
participating in signaling pathways and by reacting with enzymes that participate in processes 
that govern the cell cycle [17].  
Current treatments for orthopedic implant infections include the DAIR procedure, 
antibiotics, and silver coated implants. DAIR, which stands for debridement, antibiotic therapy, 
irrigation, and retention, is a common treatment for orthopedic implant infection. This method is 
recommended for patients whose symptoms are short-term [3]. Ceftazidime and ciprofloxacin 
were used in combination and shown to be successful against orthopedic implants infected with 
P. aeruginosa. However, this therapy was less successful at treating infections made up of 
multiple bacterial species [18]. Rifampicin is a common drug used for these infections due to its 
ability to treat Staphylococcus. However, it should be administered in tandem with another drug, 
such as levofloxacin, to prevent the bacteria from developing a resistance [19]. Antibiotic 
resistance is a major concern in medicine currently. S. aureus and P. aeruginosa are highly 
resistant microorganisms [20]. Present antibiotics are being rendered ineffective due to mutating 
bacteria that are no longer susceptible to these antibiotic treatments. Therefore, various agents 
are being investigated to either prevent the production of biofilm or disturb biofilm that already 
exists. These compounds include anti-adhesins, quorum sensing inhibitors, NSAIDs, and N-
acetylcysteine. However, more research must been done on these compounds to ensure that they 
work on a wide variety of bacterial species. [21]. 
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Many different treatments are being investigated as alternatives for treating orthopedic 
implant infection. The surface roughness and makeup of implants have been investigated to 
determine if biofilm growth varies depending on these factors. The use of materials to prevent 
adhesion entirely have also been investigated. However, these materials may also prevent 
adhesion of host cells. Coating the implant surface is also an option. Chitosan, copper, silver, and 
other materials have been investigated due to their antimicrobial and/or bactericidal properties 
[22]. Vaccines against the bacteria present in these infections and biofilms are also being 
investigated [22]. Although these coatings have shown to be effective, they do have drawbacks. 
For example, silver coatings may affect the integration between bone and implant due to its 
cytotoxic effect on various cell types [23]. Bacteriophages have been investigated as a possible 
treatment, both alone and in combination with antibiotics, to treat orthopedic implant infections. 
This particular study demonstrated that a combined therapy of antibiotics and bacteriophages 
decreased the size of the biofilm of the methicillin-resistant Staphylococcus aureus (MRSA) 
bacteria. It also showed that the bacteriophage used against P. aeruginosa lessened the bacterial 
load, but not the biofilm size. More studies are still necessary for this treatment option and a 
limit of this therapy is the necessity of finding a bacteriophage that works for each particular 
bacteria [24]. Natural products have also been studied as possible treatments for orthopedic 
implant infection. One study investigated the effectiveness of Quercus infectoria G. Olivier 
extract, which has tannic acid as a main ingredient, on the formation of MRSA biofilms. This 
study showed that this extract does have an effect on the formation of biofilm by MRSA. It 
decreased the biofilm formation of MRSA cultures, and MSSA cultures, to a lesser extent [25]. 
Antimicrobial photodynamic therapy is a treatment that combines visible light, oxygen, and a 
photosensitizer to generate reactive oxygen species to kill the pathogenic bacteria. This treatment 
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method is more effective against Gram positive bacteria because Gram negative bacteria has a 
cell wall that is difficult for the photosensitizer to penetrate. Photodynamic therapy is still an 
emerging field, so there is room for more discovery [26]. 
Bacteria of the lactobacillus genus are considered harmless microorganisms known to 
regulate host inflammatory and immune responses and are beneficial for the human microbiome. 
This particular study found that 3 strains of lactobacillus (L. fermentum, L. zeae, and L. 
paracasei) possessed properties that were able to prevent the formation of biofilm and decrease 
the virulence of P. aeruginosa [27]. A few studies have investigated beneficial bacteria as a 
therapy for orthopedic implant infection and have reported positive effects. Lactobacilli are able 
to secrete antibacterial substances such as antimicrobial peptides, lantibiotics, bacteriocins, 
microcins, lactic acid, and hydrogen peroxide. Using mechanisms including membrane 
permeabilization and interference with essential enzymes and gene expression, these molecules 
inhibit bacterial growth and/or cause death. A recent study by Zhou & Zhang investigated the 
effect of bacteriocins produced by Lactobacillus rhamnosus on S. aureus. The bacteriocins 
caused a decrease in biofilm formation and inflammation in a murine model [28]. Pro-
inflammatory cytokine release is increased following pathogenic infection and can be associated 
with significant destruction of tissue. These cytokines include IL-1β, TNF-α, and GM-CSF [29].  
Interaction of Lactobacilli with fibroblasts, epithelial and inflammatory cells, produces a very 
different cytokine release pattern and anti-inflammatory activity has been reported.  These 
studies support the possibility of an additional anti-inflammatory role that Lactobacilli may have 
in the treatment of clinical infection.   
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A candidate is cerium oxide (CeO2) nanoparticles (CNP), which is gaining significant 
and growing interest for its unprecedented auto-regenerative anti-inflammatory and antioxidant 
activity as well as reported antibacterial properties allowing for augmented tissue healing [30]. 
Cerium oxide nanoparticles (CNP) are being investigated as possible treatments for multiple 
diseases, such as those associated with E. coli, S. pneumonia, and P. vulgaris [31]. CNP is 
composed of a crystalline matrix of mixed Ce3+ and Ce4+ valence states with the ability to 
transition between the two during redox reactions imparting a well-established auto-regenerative 
anti-inflammatory and antioxidant activity to local cells. CNP works as an antioxidant by 
mimicking superoxide dismutase and catalase activity around healthy cells at physiological pH 
and scavenging reactive oxygen species. However, in the presence of bacterial cells and cancer 
cells, CNP acts in a different way. When CNP encounters cancer cells, the pH is below 7, which 
encourages CNP’s superoxide dismutase-like activity, but discourages its catalase-like activity. 
Therefore, CNP creates a lot of reactive oxygen species. In the presence of bacteria, CNP worked 
through different methods depending on whether it had direct or indirect contact with the 
bacteria. When CNP is in direct contact with the bacteria, it adheres to the surface of the bacteria 
and causes damage to the cell wall, which leads to the formation of reactive oxygen species 
inside the cell. The reactive oxygen species inside the cell cause damage to the bacteria’s DNA, 
RNA, and protein, which culminates in the death of the bacterial cell. With the indirect method, 
CNP creates reactive oxygen species outside of the cell. The reactive oxygen species cross the 
cell membrane to enter the bacterial cell and eventually kill the cell [31]. The effects of CNP 
differ based on many factors, including particle size, the presence of a coating, and the valence 
ratio. Nanoparticles, by nature, are meant to stay very small. However, they have a tendency to 
form clumps when they interact. These nanoparticles are often coated to prevent this aggregation 
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and to make them more soluble. One common coating is dextran [32]. CNP can interconvert 
between +3 and +4 valence states, which conveys different properties. Increased Ce4+ 
concentration has been shown to increase the amount of calcium deposited and to upregulate 
alkaline phosphatase (ALP) and osteocalcin (OCN), which are osteogenic markers [33]. A study 
by Ma et al. 2019 investigated the use of CNP in wound healing. They found that rough surface 
hollow CNP loaded with L-arginine were effective at killing bacteria due to their ability to 
generate reactive oxygen species when irradiated with light. The L-arginine allowed for 
increased production of nitric oxide when stimulated with lipopolysaccharide. The use of CNP 
also showed an increase in cell proliferation. In all, these particles were effective in promoting 
wound healing [34]. There is some positive data on the use of CNP and beneficial bacteria for 
treating orthopedic implant infections, but they are still relatively new fields that require more 
study. There are few studies that have investigated the beneficial bacteria that we propose to 
investigate, which is L. fermentum. There is also a gap in knowledge concerning the use of CNP 
including determining the optimal dose, Ce3+ and Ce4+ valence state ratio and particle size for 
use as an effective antimicrobial agent; and without negatively effecting host cell function and 
activity. 
The aim of this study was to investigate CNP and L. fermentum as possible treatments for 
orthopedic implant infections and will address the hypothesis, which is that both (i) the cell-free 
supernatant of L. fermentum and (ii) CNP will reduce the growth of two strains of pathogenic 
bacteria (S. aureus and P. aeruginosa) and inhibit the release of pro-inflammatory cytokines 
from macrophages with no toxic effects. It was expected that the dextran-coated CNP will work 
best. The dextran coating is expected to prevent clumping of the CNP, often seen especially at 
high concentrations.  
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MATERIALS AND METHODS 
 
Dextran-coated 70/30 Ce4+/Ce3+ 50/50 Ce4+/Ce3+ 
1 µg/mL 1 µg/mL 1 µg/mL 
10 µg/mL 10 µg/mL 10 µg/mL 
20 µg/mL 20 µg/mL 20 µg/mL 
100 µg/mL 100 µg/mL 100 µg/mL 
500 µg/mL 500 µg/mL 500 µg/mL 
800 µg/mL 800 µg/mL 800 µg/mL 
Table 1: Experimental CNP Groups 
Supplies 
 
PAO1 P. aeruginosa (ATCC® BAA-47™; Manassas, VA), freeze-dried S. aureus subsp. aureus 
Rosenbach (ATCC® 6538P™; Manassas, VA), L. fermentum (ATCC® 14931™; Manassas, 
VA), MRS broth, Luria-Bertania (LB) broth and agar plates, CNP at various concentrations and 
formulations (supplied by Dr. Sudipta Seal’s lab; UCF, Orlando, FL), XTT Cell Proliferation 
Assay Kit (ATCC® 30-1011K™; Manassas, VA), Thermo Scientific™ Sorvall™ Legend™ XT 
centrifuge (Thermo Fisher Scientific), phosphate buffered saline, gentamicin 
antibiotic, Fisherbrand™ Isotemp™ Microbiological Incubators (Fisher Scientific), RAW 
264.7 macrophages, microscope, Moticam 1080 microscope camera (Motic North America; 
British Columbia, Canada) 
 
Part 1: CNP  
 
A dynamic light scatter (DLS) machine was used to measure particle size and the following 
groups were investigated in triplicate: (1) Dextran coated CNP1 (5-10 nm in size and 50:50 
3+/4+ ratio), (2) CNP2 (30 - 100 nm in size and 30:70 3+/4+ ratio) and (3) CNP3 (30 - 100 nm 
in size and 50:50 3+/4+ ratio). DLS measures particle size by examining changes in the intensity 
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of scattered light caused by the moving particles in the sample [35]. Each CNP formulation was 
investigated at six different concentrations (i) 1 g/ml, (ii) 10 g/ml, (iii) 20 g/ml (iv) 100 
g/ml, (v) 500 g/ml, and (vi) 800 g/ml. Dextran-coated ceria particles were synthesized via a 
forced hydrolysis reaction at room temperature in presence of 1000 Da dextran. Briefly, 125 mg 
dextran was dissolved in 25 mL of de-ionized water under stirring for 15 minutes. From here, 53 
mg cerium nitrate hexahydrate was added and stirred for an additional hour to promote 
coordination of cerium ions and dextran. Formation of cerium oxide was accomplished through 
addition of 100 μL of 30% ammonium hydroxide (ACS grade) under stirring for 15 minutes. The 
solution was left standing in dark conditions for 5 days prior to use to allow polymer-coated 
particles to equilibrate/disperse in the solution (i.e. stabilize). The 50/50 CNP was synthesized 
using a wet technique as described in another paper [30]. Cerium nitrate hexahydrate was added 
to 50 mL of deionized water and dissolved completely. The Ce3+ ions were converted to cerium 
(IV) oxide through addition of 3% hydrogen peroxide to a pH below 3.5 and a final cerium 
concentration of 5 mM. Nanoparticle crystals form spontaneously. From here, the solutions were 
left standing away from light and aged for up to 30 days to allow catalytic degradation of excess 
hydrogen peroxide [30]. The 70/30 CNP was synthesized using a forced hydrolysis reaction. 1.24 
g of cerium nitrate hexahydrate was stirred in 50 mL of water for 1 hr followed by titration with 
30% ammonium hydroxide (ACS grade) to force precipitation of nanocrystalline cerium oxide 
over 4 hrs of stirring. The solution was then centrifuged at 10,000 rpm to collect the sedimented 
particles, and the sediment was washed 3x with de-ionized water. Particles were then re-
suspended in de-ionized water and ultra-sonicated for 20 minutes to disperse stable particles. 
Solutions were then left standing overnight and any further sediment was removed by manually 
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collecting supernatant of well-suspended particles [36]. Particles were used without further 
modification. 
A disposable inoculating loop was used to inoculate 10 mL of LB broth with P. 
aeruginosa or S. aureus. The bacteria was grown for approximately 24 hours in a shaking 
incubator (37°C, 120 RPM). After 24 hours, the OD600 of the sample was checked using LB 
broth as a blank. The cells were centrifuged (2500 RPM for 7 mins) and washed with PBS twice, 
and the OD600 was checked again, with PBS as the blank. The bacterial sample was diluted to 0.1 
OD, if necessary. 500 µL of the bacterial sample was spread onto LB plates using an L-shaped 
spreader. For the CNP experiments, the 5 mM stock solution of CNP for 1 hour (10 min 
increments, 70% Amp) and dilutions were made according to the calculations below. 3 filter 
paper disks were immersed in each CNP solution, positive control solution, and negative control 
solution for a minimum of 5 mins using sterile forceps/tweezers. PBS served as a negative 
control and gentamicin antibiotic (5 mg/mL) served as a positive control. The disks were 
transferred to the LB plates in a randomized pattern and incubated at 37°C. Pictures of the disk 
were taken with a microscope on days 1 and 3 and the zones of inhibition were measured. S. 
aureus was not washed and 250 µL, instead of 500 µL, of bacteria was plated. S. aureus was also 
not diluted. The zones of inhibition were not included in the results section because there wasn’t 
much change on the macro scale of the plates. The microscope pictures reveal the micro scale 
and were included in the results.  
Calculations for dilutions of the CNP stock solution 
𝐶𝑁𝑃 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛𝑠: 
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5 𝑚𝑚𝑜𝑙
1 𝐿
∗
1 𝐿
1000 𝑚𝐿
∗
1 𝑚𝑜𝑙
1000 𝑚𝑚𝑜𝑙
∗
172.115 𝑔
1 𝑚𝑜𝑙
∗
106 µ𝑔
1 𝑔
= 860.575 µ𝑔 𝑚𝐿⁄ 𝐶𝑁𝑃 
(𝑠𝑡𝑜𝑐𝑘 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛)(𝑠𝑡𝑜𝑐𝑘 𝑣𝑜𝑙𝑢𝑚𝑒) = (𝑑𝑒𝑠𝑖𝑟𝑒𝑑 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛)(𝑑𝑒𝑠𝑖𝑟𝑒𝑑 𝑣𝑜𝑙𝑢𝑚𝑒) 
1 µ𝑔 𝑚𝐿 𝐶𝑁𝑃⁄  
(860.575 µ𝑔 𝑚𝐿)(𝑥 𝑚𝐿) = (1 µ𝑔 𝑚𝐿)(1 𝑚𝐿)⁄⁄  
𝑥 = 0.0012 𝑚𝐿 = 1.2 µ𝐿 
Add 0.0012 mL (or 1.2 µL) of the CNP stock solution to 0.9988 mL of PBS to get 1 mL 
of 1 µg/mL CNP solution. 
These calculations were repeated to make all of the CNP dilutions.  
  
Figure 1: Example of line-intercept method of near image 
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Figure 2: Example of line-intercept method of far image 
Pictures were taken with the microscope at 100X magnification. Four pictures were taken for 
each disk – two near and two far. Near refers to the analysis done on the images that were taken 
with the disk interface included, as seen in Figure 1. Far refers to analysis done on images that 
were taken just outside of the disk interface, as seen in Figure 2. Pictures were taken on both day 
1 and day 3. A line-intercept method was done on all of the images. Biofilm, species, and biofilm 
+ species were determined by counting each variable as they appeared at the intersection of the 
lines and dividing by the total amount of intersections (n=195). For the effect of dose response, 
the analysis was divided by the type of CNP investigated, and further divided by the day the data 
was collected. Infection total was defined as the amount of areas that contained both biofilm and 
species out of the total areas counted. Each variable was compared and the p-values were noted. 
P-values less than or equal to 0.05 were considered significant. The infection totals were also 
compared between day 1 and day 3 and the p-values noted. For the effect of CNP formulation, 
the different types of CNP were compared at the same dose. For treatment potency, the infection 
totals near and far were compared for the same formulation, dose, and day. For the effect of CNP 
on reducing biofilm maturation, the amount of species and the amount of biofilm were added up 
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separately and the number of species were divided by the amount of biofilm. This ratio was 
represented as a percentage.  
Macrophages 
 
RAW 264.7 macrophages were cultured overnight in DMEM culture media. The cells were 
lifted, transferred to a conical tube, and pelleted in the centrifuge (500g, 5 min). The cells were 
stained with trypan blue and counted using a hemocytometer. The cells were optimized 
according to the XTT Pre-Assay Optimization Protocol [37].  
The 70/30 and 50/50 CNP was sonicated for 30 minutes. The dextran-coated CNP was not 
sonicated. The CNP dilutions were under a UV light for 20 minutes. The cells had been grown 
overnight in a 96 well plate. The media was vacuumed off and each concentration and type of 
CNP was added to the cells in triplicate. The CNP was diluted in DMEM culture media and 100 
µL of each experimental group was added to the well plate. Cells with no CNP and blank 
DMEM culture media served as controls. The well plate was returned to the incubator. The plate 
was read at 490 nm and 680 nm on days 1 and 3 according to the XTT Assay Protocol [37]. 
Part 2: L. fermentum 
 
For the cell-free supernatant experiment, the L. fermentum was grown in MRS broth in the same 
fashion as the P. aeruginosa or S. aureus. The OD600 was checked with MRS broth as a blank. 
The L. fermentum was centrifuged at 3000g for 25 minutes. The supernatant was removed. 3 
filter paper disks were immersed in the supernatant solution, positive control solution, and 
negative control solution for a minimum of 5 mins using sterile forceps/tweezers. The disks were 
transferred to the LB plates in a randomized pattern and incubated at 37°C. Pictures of the disk 
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were taken with a microscope on days 1 and 3 and the zones of inhibition were measured. S. 
aureus and P. aeruginosa were not washed and 250 µL, instead of 500 µL, of bacteria was 
plated. The bacterial samples were also not diluted.  
Statistical Analysis 
 
Statistical analysis was performed on the data collected using IBM SPSS Statistics 25. For each 
set of data, the means and standard errors were calculated. Comparisons between variables were 
carried out using nonparametric Mann-Whitney U tests and data was presented using boxplot 
graphs.  
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RESULTS  
A star (*) indicates a significant p-value (p-value ≤ 0.05). PC is the positive control, which is 
gentamicin antibiotic. NC is the negative control, which is PBS. Near counts refer to counts 
taken immediately adjacent to the disk interface, while far counts refer to counts on pictures 
taken at a designated and standardized distance away from the disk interface. For the 8x8 and 
3x3 charts, the numbers along the top and left side of the charges correspond to the labels in the 
corresponding chart. For example, in Table 2, 1 refers to dextran-coated CNP at 1 µg/mL and 2 
refers to dextran-coated CNP at 10 µg/mL. In table 2, the box between 1 and 2 refers to the 
comparison between dextran-coated CNP at 1 µg/mL and dextran-coated CNP at 10 µg/mL. 
Part 1: CNP 
Effect of Dose Response 
 
Label Dose Day 1 Mean Standard Error 
1 Dextran 1 µg/mL 88.63% 11.37% 
2 Dextran 10 µg/mL 91.37% 6.46% 
3 Dextran 20 µg/mL 57.69% 21.10% 
4 Dextran 100 µg/mL 40.42% 17.58% 
5 Dextran 500 µg/mL 57.18% 9.40% 
6 Dextran 800 µg/mL 42.82% 29.55% 
7 PC 0% 0% 
8 NC 94.78% 2.14% 
Table 2: Infection totals of day 1 dextran CNP, near, P. aeruginosa 
  
1 2 3 4 5 6 7 8 
1 X X X X X X X X 
2 0.817 X X X X X X X 
3 0.268 0.127 X X X X X X 
4 0.121 0.05* 0.827 X X X X X 
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5 0.121 0.05* 0.827 0.275 X X X X 
6 0.246 0.376 0.827 0.827 0.513 X X X 
7 0.034* 0.037* 0.037* 0.037* 0.037* 0.037* X X 
8 0.5 0.825 0.046* 0.046* 0.046* 0.507 0.034* X 
Table 3: Comparisons of infection totals by dose of day 1 dextran CNP, near, P. aeruginosa 
Dextran-coated CNP at 100 µg/mL displayed a significantly less bacterial growth and biofilm 
formation when compared to dextran-coated CNP at 10 µg/mL. Significantly less bacterial 
growth and biofilm formation was seen when dextran-coated CNP at 500 µg/mL was compared 
to dextran-coated CNP at 10 µg/mL. There was a significant difference between the positive 
control and all other variables. The negative control displayed significantly more bacterial 
growth and biofilm formation when compared to dextran-coated CNP at 20, 100, and 500 
µg/mL. 
 
Label Dose Day 3 Mean Standard Error 
1 Dextran 1 µg/mL 100% 0% 
2 Dextran 10 µg/mL 100% 0% 
3 Dextran 20 µg/mL 85.73% 14.27% 
4 Dextran 100 µg/mL 73.85% 13.38% 
5 Dextran 500 µg/mL 62.56% 14.62% 
6 Dextran 800 µg/mL 38.89% 25.77% 
7 PC 0% 0% 
8 NC 99.66% 0.34% 
Table 4: Infection totals of day 3 dextran CNP, near, P. aeruginosa 
  
1 2 3 4 5 6 7 8 
1 X X X X X X X X 
2 1 X X X X X X X 
3 0.317 0.317 X X X X X X 
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4 0.121 0.121 0.487 X X X X X 
5 0.037* 0.037* 0.121 0.275 X X X X 
6 0.037* 0.037* 0.121 0.275 0.275 X X X 
7 0.025* 0.025* 0.034* 0.037* 0.037* 0.037* X X 
8 0.317 0.317 0.796 0.246 0.046* 0.046* 0.034* X 
Table 5: Comparisons of infection totals by dose of day 3 dextran CNP, near, P. aeruginosa 
Dextran-coated CNP at 500 µg/mL displayed significantly less bacterial growth and biofilm 
formation when compared to dextran-coated CNP at 1 and 10 µg/mL. Dextran-coated CNP at 
800 µg/mL displayed significantly less bacterial growth and biofilm formation when compared 
to dextran-coated CNP at 1 and 10 µg/mL. There was a significant difference between the 
positive control and all other variables. The negative control displayed significantly more 
bacterial growth and biofilm formation when compared to dextran-coated CNP at 500 and 800 
µg/mL. 
 
Groups P-value 
Dextran Day 1 1 µg/mL 0.317 
Dextran Day 3 1 µg/mL 
Dextran Day 1 10 µg/mL 0.121 
Dextran Day 3 10 µg/mL 
Dextran Day 1 20 µg/mL 0.268 
Dextran Day 3 20 µg/mL 
Dextran Day 1 100 µg/mL 0.275 
Dextran Day 3 100 µg/mL 
Dextran Day 1 500 µg/mL 0.827 
Dextran Day 3 500 µg/mL 
Dextran Day 1 800 µg/mL 0.822 
Dextran Day 3 800 µg/mL 
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PC Day 1  1 
PC Day 3 
NC Day 1 0.043* 
NC Day 3 
Table 6: Comparisons of infection totals by day, dextran CNP, near, P. aeruginosa 
There was a significant difference between bacterial growth and biofilm formation between days 
1 and 3 of the negative control.  
 
 
Figure 3: Dextran CNP's Effect on P. aeruginosa Infection 
 
Label  Dose Day 1 Mean Standard Error 
1 50/50 1 µg/mL 83.72% 10.13% 
2 50/50 10 µg/mL 44.70% 20.23% 
3 50/50 20 µg/mL 78.29% 6.07% 
4 50/50 100 µg/mL 65.73% 17.61% 
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5 50/50 500 µg/mL 84.27% 5.74% 
6 50/50 800 µg/mL 77.78% 9.20% 
7 PC 0% 0% 
8 NC 94.78% 2.14% 
Table 7: Infection totals of day 1 50/50 CNP, near, P. aeruginosa 
 
 
1 2 3 4 5 6 7 8 
1 X X X X X X X X 
2 0.083 X X X X X X X 
3 0.564 0.127 X X X X X X 
4 0.564 0.827 0.513 X X X X X 
5 0.564 0.05* 0.275 0.513 X X X X 
6 0.564 0.127 0.827 0.513 0.275 X X X 
7 0.053 0.037* 0.037* 0.037* 0.037* 0.037* X X 
8 0.236 0.046* 0.046* 0.507 0.121 0.046* 0.034* X 
Table 8: Comparisons of infection totals by dose of day 1 50/50 CNP, near, P. aeruginosa 
50/50 CNP at 500 µg/mL showed significantly more bacterial growth and biofilm formation 
when compared to 50/50 CNP at 10 µg/mL. There was a significant difference between the 
positive control and all other variables, except 50/50 CNP at 1 µg/mL. The negative control 
displayed significantly more bacterial growth and biofilm formation when compared to 50/50 
CNP at 10, 20, and 800 µg/mL. 
 
Label  Dose Day 3 Mean Standard Error 
1 50/50 1 µg/mL 100% 0% 
2 50/50 10 µg/mL 68.63% 26.17% 
3 50/50 20 µg/mL 98.21% 1.79% 
4 50/50 100 µg/mL 84.19% 8.60% 
5 50/50 500 µg/mL 83.93% 8.56% 
6 50/50 800 µg/mL 87.95% 6.05% 
7 PC 0% 0% 
8 NC 99.66% 0.34% 
Table 9: Infection totals of day 3 50/50 CNP, near, P. aeruginosa 
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1 2 3 4 5 6 7 8 
1 X X X X X X X X 
2 0.197 X X X X X X X 
3 0.414 0.246 X X X X X X 
4 0.076 0.827 0.121 X X X X X 
5 0.197 1 0.246 0.827 X X X X 
6 0.197 1 0.246 0.827 0.5 X X X 
7 0.046* 0.037* 0.034* 0.037* 0.037* 0.037* X X 
8 0.414 0.246 0.796 0.046* 0.246 0.246 0.034* X 
Table 10: Comparisons of infection totals by dose of day 3 50/50 CNP, near, P. aeruginosa 
There was a significant difference between the positive control and all other variables. There was 
a significant difference between the negative control and 50/50 CNP at 100 µg/mL. 
 
Groups P-value 
50/50 Day 1 1 µg/mL 0.102 
50/50 Day 3 1 µg/mL 
50/50 Day 1 10 µg/mL 0.275 
50/50 Day 3 10 µg/mL 
50/50 Day 1 20 µg/mL 0.046* 
50/50 Day 3 20 µg/mL 
50/50 Day 1 100 µg/mL 0.513 
50/50 Day 3 100 µg/mL 
50/50 Day 1 500 µg/mL 0.827 
50/50 Day 3 500 µg/mL 
50/50 Day 1 800 µg/mL 0.827 
50/50 Day 3 800 µg/mL 
PC Day 1  1 
PC Day 3 
NC Day 1 0.043* 
NC Day 3 
Table 11: Comparisons of infection totals by day, 50/50 CNP, near, P. aeruginosa 
There was a significant difference between bacterial growth and biofilm formation between days 
1 and 3 of the negative control and 50/50 CNP at 20 µg/mL.  
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Figure 4:50/50 CNP's Effect on P. aeruginosa Infection 
 
Label Dose Day 1 Mean Standard Error 
1 70/30 1 µg/mL 96.24% 2.15% 
2 70/30 10 µg/mL 58.38% 29.25% 
3 70/30 20 µg/mL 79.23% 14.21% 
4 70/30 100 µg/mL 55.64% 22.51% 
5 70/30 500 µg/mL 75.39% 15.75% 
6 70/30 800 µg/mL 52.82% 19.03% 
7 PC 0% 0% 
8 NC 94.78% 2.14% 
Table 12: Infection totals of day 1 70/30 CNP, near, P. aeruginosa 
 
 
1 2 3 4 5 6 7 8 
1 X X X X X X X X 
2 0.05* X X X X X X X 
3 0.376 0.513 X X X X X X 
4 0.127 0.827 0.513 X X X X X 
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5 0.275 0.827 0.513 0.513 X X X X 
6 0.05* 0.827 0.275 0.827 0.513 X X X 
7 0.037* 0.121 0.037* 0.037* 0.037* 0.037* X X 
8 0.825 0.121 0.507 0.121 0.507 0.046* 0.034* X 
Table 13: Comparisons of infection totals by dose of day 1 70/30 CNP, near, P. aeruginosa 
70/30 CNP at 10 µg/mL showed significantly less bacterial growth and biofilm formation when 
compared to 70/30 CNP at 1 µg/mL. 70/30 CNP at 800 µg/mL showed significantly less 
bacterial growth and biofilm formation when compared to 70/30 CNP at 1 µg/mL. There was a 
significant difference between the positive control and all other variables, except 70/30 CNP at 
10 µg/mL. The negative control displayed a significant difference when compared to 70/30 CNP 
at 800 µg/mL. 
 
 
Label Dose Day 3 Mean Standard Error 
1 70/30 1 µg/mL 100% 0% 
2 70/30 10 µg/mL 66.24% 33.12% 
3 70/30 20 µg/mL 100% 0% 
4 70/30 100 µg/mL 61.11% 20.26% 
5 70/30 500 µg/mL 100% 0% 
6 70/30 800 µg/mL 68.72% 18.93% 
7 PC 0% 0% 
8 NC 99.66% 0.34% 
Table 14: Infection totals of day 3 70/30 CNP, near, P. aeruginosa 
 
 
1 2 3 4 5 6 7 8 
1 X X X X X X X X 
2 0.121 X X X X X X X 
3 1 0.121 X X X X X X 
4 0.121 1 0.121 X X X X X 
5 1 0.121 1 0.121 X X X X 
6 0.121 1 0.121 0.658 0.121 X X X 
7 0.025* 0.121 0.025* 0.037* 0.025* 0.037* X X 
8 0.317 0.246 0.317 0.246 0.317 0.246 0.034* X 
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Table 15: Comparisons of infection totals by dose of day 3 70/30 CNP, near, P. aeruginosa 
There was a significant difference between the positive control and all other variables, except 
70/30 CNP at 10 µg/mL. 
 
 
Groups P-value 
70/30 Day 1 1 µg/mL 0.121 
70/30 Day 3 1 µg/mL 
70/30 Day 1 10 µg/mL 0.376 
70/30 Day 3 10 µg/mL 
70/30 Day 1 20 µg/mL 0.121 
70/30 Day 3 20 µg/mL 
70/30 Day 1 100 µg/mL 0.827 
70/30 Day 3 100 µg/mL 
70/30 Day 1 500 µg/mL 0.037* 
70/30 Day 3 500 µg/mL 
70/30 Day 1 800 µg/mL 0.513 
70/30 Day 3 800 µg/mL 
PC Day 1  1 
PC Day 3 
NC Day 1 0.043* 
NC Day 3 
Table 16: Comparisons of infection totals by day, 70/30 CNP, near, P. aeruginosa 
There was a significant difference between bacterial growth and biofilm formation between days 
1 and 3 of the negative control and 70/30 CNP at 500 µg/mL.  
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Figure 5: 70/30 CNP's Effect on P. aeruginosa Infection 
Effect of CNP formulation 
 
Label  Type Day 1 Mean Standard Error 
1 Dextran 1 µg/mL 88.63% 11.37% 
2 50/50 1 µg/mL 83.72% 10.13% 
3 70/30 1 µg/mL 96.24% 2.15% 
Table 17: Infection totals of CNP by type, 1 µg/mL, day 1, near, P. aeruginosa 
 
1 2 3 
1 X X X 
2 0.554 X X 
3 0.817 0.248 X 
Table 18: Comparison of infection totals by type of CNP, 1 µg/mL, day 1, near, P. aeruginosa 
Label  Type Day 3 Mean Standard Error 
1 Dextran 1 µg/mL 100% 0% 
2 50/50 1 µg/mL 100% 0% 
3 70/30 1 µg/mL 100% 0% 
Table 19: Infection totals of CNP by type, 1 µg/mL, day 3, near, P. aeruginosa 
 
1 2 3 
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1 X X X 
2 1 X X 
3 1 1 X 
Table 20: Comparison of infection totals by type of CNP, 1 µg/mL, day 3, near, P. aeruginosa 
  
Figure 6: CNP Effect on P. aeruginosa Infection by Type - 1 µg/mL 
Label  Type Day 1 Mean Standard Error 
1 Dextran 10 µg/mL 91.37% 6.46% 
2 50/50 10 µg/mL 44.70% 20.23% 
3 70/30 10 µg/mL 58.38% 29.25% 
Table 21: Infection totals of CNP by type, 10 µg/mL, day 1, near, P. aeruginosa 
 
1 2 3 
1 X X X 
2 0.05* X X 
3 0.275 0.513 X 
Table 22: Comparison of infection totals by type of CNP, 10 µg/mL, day 1, near, P. aeruginosa 
There was a significant difference in biofilm formation and bacterial growth between dextran-
coated CNP and 50/50 CNP at 10 µg/mL. 50/50 CNP at 10 µg/mL showed significantly less 
bacterial growth and biofilm formation than dextran-coated CNP. 
 27 
 
Label  Type Day 3 Mean Standard Error 
1 Dextran 10 µg/mL 100% 0% 
2 50/50 10 µg/mL 68.63% 26.17% 
3 70/30 10 µg/mL 66.24% 33.12% 
Table 23: Infection totals of CNP by type, 10 µg/mL, day 3, near, P. aeruginosa 
 
1 2 3 
1 X X X 
2 0.121 X X 
3 0.121 1 X 
Table 24: Comparison of infection totals by type of CNP, 10 µg/mL, day 3, near, P. aeruginosa 
 
Figure 7: CNP Effect on P. aeruginosa Infection by Type - 10 µg/mL 
Label  Type Day 1 Mean Standard Error 
1 Dextran 20 µg/mL 57.69% 21.10% 
2 50/50 20 µg/mL 78.29% 6.07% 
3 70/30 20 µg/mL 79.23% 14.21% 
Table 25: Infection totals of CNP by type, 20 µg/mL, day 1, near, P. aeruginosa 
 
1 2 3 
1 X X X 
2 0.513 X X 
3 0.275 0.827 X 
Table 26: Comparison of infection totals by type of CNP, 20 µg/mL, day 1, near, P. aeruginosa 
Label  Type Day 3 Mean Standard Error 
1 Dextran 20 µg/mL 85.73% 14.27% 
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2 50/50 20 µg/mL 98.21% 1.79% 
3 70/30 20 µg/mL 100% 0% 
Table 27: Infection totals of CNP by type, 20 µg/mL, day 3, near, P. aeruginosa 
 
1 2 3 
1 X X X 
2 0.796 X X 
3 0.317 0.317 X 
Table 28: Comparison of infection totals by type of CNP, 20 µg/mL, day 3, near, P. aeruginosa 
 
Figure 8: CNP Effect on P. aeruginosa Infection by Type - 20 µg/mL 
Label  Type Day 1 Mean Standard Error 
1 Dextran 100 µg/mL 40.42% 17.58% 
2 50/50 100 µg/mL 65.73% 17.61% 
3 70/30 100 µg/mL 55.64% 22.51% 
Table 29: Infection totals of CNP by type, 100 µg/mL, day 1, near, P. aeruginosa 
 
1 2 3 
1 X X X 
2 0.275 X X 
3 0.827 0.513 X 
Table 30: Comparison of infection totals by type of CNP, 100 µg/mL, day 1, near, P. aeruginosa 
Label  Type Day 3 Mean Standard Error 
1 Dextran 100 µg/mL 73.85% 13.37% 
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2 50/50 100 µg/mL 84.19% 8.60% 
3 70/30 100 µg/mL 61.11% 20.26% 
Table 31: Infection totals of CNP by type, 100 µg/mL, day 3, near, P. aeruginosa 
 
1 2 3 
1 X X X 
2 0.513 X X 
3 0.376 0.513 X 
Table 32: Comparison of infection totals by type of CNP, 100 µg/mL, day 3, near, P. aeruginosa 
 
Figure 9: CNP Effect on P. aeruginosa Infection by Type - 100 µg/mL 
Label  Type Day 1 Mean Standard Error 
1 Dextran 500 µg/mL 57.18% 9.40% 
2 50/50 500 µg/mL 84.27% 5.74% 
3 70/30 500 µg/mL 75.39% 15.75% 
Table 33: Infection totals of CNP by type, 500 µg/mL, day 1, near, P. aeruginosa 
 
1 2 3 
1 X X X 
2 0.127 X X 
3 0.376 0.827 X 
Table 34: Comparison of infection totals by type of CNP, 500 µg/mL, day 1, near, P. aeruginosa 
Label  Type Day 3 Mean Standard Error 
1 Dextran 500 µg/mL 62.56% 14.62% 
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2 50/50 500 µg/mL 83.93% 8.56% 
3 70/30 500 µg/mL 100% 0% 
Table 35: Infection totals of CNP by type, 500 µg/mL, day 3, near, P. aeruginosa 
 
1 2 3 
1 X X X 
2 0.275 X X 
3 0.037* 0.121 X 
Table 36: Comparison of infection totals by type of CNP, 500 µg/mL, day 3, near, P. aeruginosa 
There was a significant difference in biofilm formation and bacterial growth between dextran-
coated CNP and 70/30 CNP at 500 µg/mL. Dextran-coated CNP at 500 µg/mL significantly less 
bacterial growth and biofilm formation when compared to 70/30 CNP at 500 µg/mL. 
 
Figure 10: CNP Effect on P. aeruginosa Infection by Type - 500 µg/mL 
Label  Type Day 1 Mean Standard Error 
1 Dextran 800 µg/mL 42.82% 29.55% 
2 50/50 800 µg/mL 77.78% 9.20% 
3 70/30 800 µg/mL 52.82% 19.03% 
Table 37: Infection totals of CNP by type, 800 µg/mL, day 1, near, P. aeruginosa 
 
1 2 3 
1 X X X 
2 0.513 X X 
3 0.827 0.275 X 
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Table 38: Comparison of infection totals by type of CNP, 800 µg/mL, day 1, near, P. aeruginosa 
Label  Type Day 3 Mean Standard Error 
1 Dextran 800 µg/mL 38.89% 25.77% 
2 50/50 800 µg/mL 87.95% 6.05% 
3 70/30 800 µg/mL 68.72% 18.93% 
Table 39: Infection totals of CNP by type, 800 µg/mL, day 3, near, P. aeruginosa 
 
1 2 3 
1 X X X 
2 0.275 X X 
3 0.275 0.376 X 
Table 40: Comparison of infection totals by type of CNP, 800 µg/mL, day 3, near, P. aeruginosa 
 
Figure 11: CNP Effect on P. aeruginosa Infection by Type - 800 µg/mL 
CNP Potency 
Groups P-value 
Dextran Day 1 1 µg/mL Near 0.487 
Dextran Day 1 1 µg/mL Far 
Dextran Day 1 10 µg/mL Near 0.05* 
Dextran Day 1 10 µg/mL Far 
Dextran Day 1 20 µg/mL Near 0.513 
Dextran Day 1 20 µg/mL Far 
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Dextran Day 1 100 µg/mL Near 0.275 
Dextran Day 1 100 µg/mL Far 
Dextran Day 1 500 µg/mL Near 0.127 
Dextran Day 1 500 µg/mL Far 
Dextran Day 1 800 µg/mL Near 0.513 
Dextran Day 1 800 µg/mL Far 
PC Day 1 Near 1 
PC Day 1 Far 
NC Day 1 Near 0.507 
NC Day 1 Far 
Table 41: Comparison of infection totals on day 1, near and far, dextran, P. aeruginosa 
There was a significant difference in biofilm formation and bacterial growth between the near 
and far counts of dextran-coated CNP on day 1 at 10 µg/mL. 
Groups P-value 
Dextran Day 3 1 µg/mL Near 1 
Dextran Day 3 1 µg/mL Far 
Dextran Day 3 10 µg/mL Near 0.121 
Dextran Day 3 10 µg/mL Far 
Dextran Day 3 20 µg/mL Near 0.796 
Dextran Day 3 20 µg/mL Far 
Dextran Day 3 100 µg/mL Near 1 
Dextran Day 3 100 µg/mL Far 
Dextran Day 3 500 µg/mL Near 0.513 
Dextran Day 3 500 µg/mL Far 
Dextran Day 3 800 µg/mL Near 0.275 
Dextran Day 3 800 µg/mL Far 
PC Day 3 Near 1 
PC Day 3 Far 
NC Day 3 Near 0.487 
NC Day 3 Far 
Table 42: Comparison of infection totals on day 3, near and far, dextran, P. aeruginosa 
Groups P-value 
50/50 Day 1 1 µg/mL Near 0.439 
50/50 Day 1 1 µg/mL Far 
50/50 Day 1 10 µg/mL Near 0.827 
50/50 Day 1 10 µg/mL Far 
50/50 Day 1 20 µg/mL Near 0.827 
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50/50 Day 1 20 µg/mL Far 
50/50 Day 1 100 µg/mL Near 0.827 
50/50 Day 1 100 µg/mL Far 
50/50 Day 1 500 µg/mL Near 0.827 
50/50 Day 1 500 µg/mL Far 
50/50 Day 1 800 µg/mL Near 0.513 
50/50 Day 1 800 µg/mL Far 
Table 43: Comparison of infection totals on day 1, near and far, 50/50, P. aeruginosa 
Groups P-value 
50/50 Day 3 1 µg/mL Near 1 
50/50 Day 3 1 µg/mL Far 
50/50 Day 3 10 µg/mL Near 0.487 
50/50 Day 3 10 µg/mL Far 
50/50 Day 3 20 µg/mL Near 0.796 
50/50 Day 3 20 µg/mL Far 
50/50 Day 3 100 µg/mL Near 0.268 
50/50 Day 3 100 µg/mL Far 
50/50 Day 3 500 µg/mL Near 0.827 
50/50 Day 3 500 µg/mL Far 
50/50 Day 3 800 µg/mL Near 0.246 
50/50 Day 3 800 µg/mL Far 
Table 44: Comparison of infection totals on day 3, near and far, 50/50, P. aeruginosa 
Groups P-value 
70/30 Day 1 1 µg/mL Near 0.376 
70/30 Day 1 1 µg/mL Far 
70/30 Day 1 10 µg/mL Near 0.827 
70/30 Day 1 10 µg/mL Far 
70/30 Day 1 20 µg/mL Near 0.658 
70/30 Day 1 20 µg/mL Far 
70/30 Day 1 100 µg/mL Near 0.513 
70/30 Day 1 100 µg/mL Far 
70/30 Day 1 500 µg/mL Near 0.827 
70/30 Day 1 500 µg/mL Far 
70/30 Day 1 800 µg/mL Near 0.275 
70/30 Day 1 800 µg/mL Far 
Table 45: Comparison of infection totals on day 1, near and far, 70/30, P. aeruginosa 
Groups P-value 
70/30 Day 3 1 µg/mL Near 0.317 
70/30 Day 3 1 µg/mL Far 
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70/30 Day 3 10 µg/mL Near 1 
70/30 Day 3 10 µg/mL Far 
70/30 Day 3 20 µg/mL Near 1 
70/30 Day 3 20 µg/mL Far 
70/30 Day 3 100 µg/mL Near 0.246 
70/30 Day 3 100 µg/mL Far 
70/30 Day 3 500 µg/mL Near 0.317 
70/30 Day 3 500 µg/mL Far 
70/30 Day 3 800 µg/mL Near 0.246 
70/30 Day 3 800 µg/mL Far 
Table 46: Comparison of infection totals on day 3, near and far, 70/30, P. aeruginosa 
Effect of CNP on reducing biofilm maturation 
Note: The percentages are a ratio of species:biofilm 
Dose Species Biofilm  Percentage 
Dextran 1 µg/mL 0 679 0.00% 
Dextran 10 µg/mL 14 185 7.57% 
Dextran 20 µg/mL 0 169 0.00% 
Dextran 100 µg/mL 36 89 40.45% 
Dextran 500 µg/mL 3 298 1.01% 
Dextran 800 µg/mL 4 193 2.07% 
PC 0 0 N/A 
NC 0 56 0.00% 
Table 47: Dextran CNP's effect on biofilm maturation, near, day 1, P. aeruginosa 
Dose Species Biofilm  Percentage 
Dextran 1 µg/mL 25 442 5.66% 
Dextran 10 µg/mL 0 0 N/A 
Dextran 20 µg/mL 15 342 4.39% 
Dextran 100 µg/mL 26 320 8.13% 
Dextran 500 µg/mL 0 108 0.00% 
Dextran 800 µg/mL 0 107 0.00% 
PC 0 0 N/A 
NC 6 0 N/A 
Table 48: Dextran CNP's effect on biofilm maturation, near, day 3, P. aeruginosa 
Data counts near the disk interface of negative control displayed more species than biofilm.  
Dose Species Biofilm  Percentage 
50/50 1 µg/mL 0 170 0.00% 
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50/50 10 µg/mL 4 195 2.05% 
50/50 20 µg/mL 25 64 39.06% 
50/50 100 µg/mL 4 189 2.12% 
50/50 500 µg/mL 0 90 0.00% 
50/50 800 µg/mL 18 174 10.34% 
PC 0 0 N/A 
NC 0 56 0.00% 
Table 49: 50/50 CNP's effect on biofilm maturation, near, day 1, P. aeruginosa 
Dose Species Biofilm  Percentage 
50/50 1 µg/mL 3 48 6.25% 
50/50 10 µg/mL 30 365 8.22% 
50/50 20 µg/mL 22 5 440.00% 
50/50 100 µg/mL 0 0 N/A 
50/50 500 µg/mL 4 30 13.33% 
50/50 800 µg/mL 134 7 1914.29% 
PC 0 0 N/A 
NC 6 0 N/A 
Table 50: 50/50 CNP's effect on biofilm maturation, near, day 3, P. aeruginosa 
Data counts near the disk interface of 50/50 CNP at 20 and 800 µg/mL displayed more species 
than biofilm. Data counts near the disk interface of the negative control displayed more species 
than biofilm.  
Dose Species Biofilm  Percentage 
70/30 1 µg/mL 0 406 0.00% 
70/30 10 µg/mL 0 122 0.00% 
70/30 20 µg/mL 21 8 262.50% 
70/30 100 µg/mL 8 40 20.00% 
70/30 500 µg/mL 21 49 42.86% 
70/30 800 µg/mL 73 23 317.39% 
PC 0 0 N/A 
NC 0 56 0.00% 
Table 51: 70/30 CNP's effect on biofilm maturation, near, day 1, P. aeruginosa 
Data counts near the disk interface of 70/30 CNP at 20 and 800 µg/mL displayed more species 
than biofilm.  
Dose Species Biofilm  Percentage 
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70/30 1 µg/mL 0 0 N/A 
70/30 10 µg/mL 0 79 0.00% 
70/30 20 µg/mL 0 0 N/A 
70/30 100 µg/mL 119 0 N/A 
70/30 500 µg/mL 19 136 13.97% 
70/30 800 µg/mL 109 0 N/A 
PC 0 0 N/A 
NC 6 0 N/A 
Table 52: 70/30 CNP's effect on biofilm maturation, near, day 3, P. aeruginosa 
Data counts near the disk interface of 70/30 CNP at 100 and 800 µg/mL displayed more species 
than biofilm. Data counts near the disk interface of the negative control displayed more species 
than biofilm.  
XTT Assay 
 
CNP Concentration Mean Absorbance Standard Error 
800µg/mL 0.124 0.002 
500µg/mL 0.361 0.016 
100µg/mL 0.760 0.145 
20µg/mL 0.961 0.099 
10µg/mL 0.832 0.095 
1µg/mL 0.792 0.056 
0µg/mL 0.095 0.002 
Media 0.234 0.003 
Table 53: Absorbance of dextran CNP, day 1 
All of the dextran-coated CNP except 800 µg/mL demonstrated an absorbance value higher than 
the media. All of the experimental groups demonstrated an absorbance value higher than the 0 
µg/mL group. 
CNP Concentration Mean Absorbance Standard Error 
800µg/mL 0.137 0.001 
500µg/mL 0.657 0.104 
100µg/mL 1.925 0.109 
 37 
 
20µg/mL 1.779 0.254 
10µg/mL 1.831 0.236 
1µg/mL 2.323 0.123 
0µg/mL 2.139 0.024 
Table 54: Absorbance of dextran CNP, day 3 
Dextran-coated CNP at 1 µg/mL showed an absorbance value higher than the absorbance value 
for the 0 µg/mL.  
 
Figure 12: XTT Assay of Dextran CNP 
 
CNP Concentration Mean Absorbance Standard Error 
800µg/mL 0.165 0.004 
500µg/mL 0.544 0.025 
100µg/mL 0.806 0.098 
20µg/mL 0.847 0.081 
10µg/mL 0.820 0.097 
1µg/mL 0.844 0.069 
0µg/mL 0.095 0.002 
Media 0.234 0.003 
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Table 55: Absorbance of 70/30 CNP, day 1 
All of the 70/30 experimental groups except 800 µg/mL demonstrated an absorbance value 
higher than the absorbance value for the media control group. All of the experimental groups 
demonstrated an absorbance value higher than the absorbance value for the 0 µg/mL control 
group.  
CNP Concentration Mean Absorbance Standard Error 
800µg/mL 0.148 0.001 
500µg/mL 1.043 0.112 
100µg/mL 2.051 0.062 
20µg/mL 2.195 0.120 
10µg/mL 2.269 0.200 
1µg/mL 2.209 0.158 
0µg/mL 2.139 0.024 
Table 56: Absorbance of 70/30 CNP, day 3 
70/30 CNP at 1, 10, and 20 µg/mL showed an absorbance value higher than that of the 0 µg/mL 
control group.  
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Figure 13: XTT Assay of 70/30 CNP 
CNP Concentration Mean Absorbance Standard Error 
800µg/mL 0.167 0.008 
500µg/mL 0.134 0.001 
100µg/mL 0.574 0.186 
20µg/mL 0.861 0.068 
10µg/mL 0.830 0.079 
1µg/mL 0.821 0.055 
0µg/mL 0.095 0.002 
Media 0.234 0.003 
Table 57: Absorbance of 50/50 CNP, day 1 
All of the 50/50 groups except 500 µg/mL and 800 µg/mL showed an absorbance value higher 
than that of the media control group. All of the experimental groups showed an absorbance value 
higher than that of the 0 µg/mL control group.  
 
CNP Concentration Mean Absorbance Standard Error 
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800µg/mL 0.232 0.051 
500µg/mL 0.125 0.003 
100µg/mL 1.693 0.081 
20µg/mL 1.970 0.074 
10µg/mL 2.060 0.047 
1µg/mL 1.454 0.608 
0µg/mL 2.139 0.024 
Table 58: Absorbance of 50/50 CNP, day 3 
None of the experimental groups showed an absorbance value higher than that of the 0 µg/mL 
control group.  
 
Figure 14: XTT Assay of 50/50 CNP 
 
Part 2: Beneficial Bacteria 
Effect of dose response 
Label Treatment Day 1 Mean Standard Error 
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1 LF 74.62% 4.30% 
2 PC 0% 0% 
3 NC 76.41% 12.36% 
Table 59: Infection totals of day 1 L. fermentum, near, S. aureus 
 
1 2 3 
1 X X X 
2 0.037* X X 
3 0.827 0.037* X 
Table 60: Comparison of infection totals by treatment, day 1 L. fermentum, near, S. aureus 
The positive control showed a significant difference in biofilm formation and bacterial growth of 
S. aureus when compared to L. fermentum and negative control.  
Label Treatment Day 3 Mean Standard Error 
1 LF 75.81% 3.82% 
2 PC 0% 0% 
3 NC 71.03% 16.39% 
Table 61: Infection totals of day 3 L. fermentum, near, S. aureus 
 
1 2 3 
1 X X X 
2 0.037* X X 
3 0.827 0.037* X 
Table 62: Comparison of infection totals by treatment, day 3 L. fermentum, near, S. aureus 
The positive control showed a significant difference in biofilm formation and bacterial growth of 
S. aureus when compared to L. fermentum and negative control.  
Groups P-value 
LF Day 1 0.827 
LF Day 3 
PC Day 1 1 
PC Day 3 
NC Day 1 0.513 
NC Day 3 
Table 63: Comparisons of infection totals by day, L. fermentum, near, S. aureus 
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Figure 15: L. fermentum's Effect on S. aureus Infection 
Label Treatment Day 1 Mean Standard Error 
1 LF 10.43% 10.43% 
2 PC 0% 0% 
3 NC 52.82% 3.41% 
Table 64: Infection totals of day 1 L. fermentum, near, P. aeruginosa 
 
1 2 3 
1 X X X 
2 0.317 X X 
3 0.046* 0.037* X 
Table 65: Comparison of infection totals by treatment, day 1 L. fermentum, near, P. aeruginosa 
The positive control showed a significant difference in biofilm formation and bacterial growth of 
P. aeruginosa when compared to the negative control. L. fermentum showed a significant 
difference when compared to the negative control.  
Label Treatment Day 3 Mean Standard Error 
1 LF 10.99% 10.61% 
2 PC 0% 0% 
3 NC 48.12% 6.15% 
Table 66: Infection totals of day 3 L. fermentum, near, P. aeruginosa 
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1 2 3 
1 X X X 
2 0.037* X X 
3 0.05* 0.037* X 
Table 67: Comparison of infection totals by treatment, day 3 L. fermentum, near, P. aeruginosa 
The positive control showed a significant difference in biofilm formation and bacterial growth of 
P. aeruginosa when compared to the negative control. L. fermentum showed a significant 
difference when compared to the positive and negative controls.  
Groups P-value 
LF Day 1 0.268 
LF Day 3 
PC Day 1 1 
PC Day 3 
NC Day 1 0.275 
NC Day 3 
Table 68: Comparisons of infection totals by day, L. fermentum, near, P. aeruginosa 
 
Figure 16: L. fermentum's Effect on P.aeruginosa Infection 
L. fermentum Potency 
Groups P-value 
LF Day 1 Near 0.05* 
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LF Day 1 Far 
PC Day 1 Near 1 
PC Day 1 Far 
NC Day 1 Near 0.127 
NC Day 1 Far 
Table 69: Comparison of infection totals on day 1, near and far, S. aureus 
There was a significant difference in biofilm formation and bacterial growth of S. aureus 
between the near and far counts of L. fermentum on day 1. 
Groups P-value 
LF Day 3 Near 0.05* 
LF Day 3 Far 
PC Day 3 Near 1 
PC Day 3 Far 
NC Day 3 Near 0.184 
NC Day 3 Far 
Table 70: Comparison of infection totals on day 3, near and far, S. aureus 
There was a significant difference in biofilm formation and bacterial growth of S. aureus 
between the near and far counts of L. fermentum on day 3. 
Groups P-value 
LF Day 1 Near 0.037* 
LF Day 1 Far 
PC Day 1 Near 1 
PC Day 1 Far 
NC Day 1 Near 0.05* 
NC Day 1 Far 
Table 71: Comparison of infection totals on day 1, near and far, P. aeruginosa 
There was a significant difference in biofilm formation and bacterial growth of S. aureus 
between the near and far counts of L. fermentum and the negative control on day 1. 
Groups P-value 
LF Day 3 Near 0.513 
LF Day 3 Far 
PC Day 3 Near 1 
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PC Day 3 Far 
NC Day 3 Near 0.275 
NC Day 3 Far 
Table 72: Comparison of infection totals on day 3, near and far, P. aeruginosa 
Effect of L. fermentum on reducing biofilm maturation 
Dose Species Biofilm  Percentage 
LF 0 0 N/A 
PC 0 0 N/A 
NC 0 0 N/A 
Table 73: L. fermentum's effect on biofilm maturation, near, day 1, S. aureus 
Dose Species Biofilm  Percentage 
LF 0 0 N/A 
PC 0 0 N/A 
NC 0 0 N/A 
Table 74: L. fermentum's effect on biofilm maturation, near, day 3, S. aureus 
Dose Species Biofilm  Percentage 
LF 0 121 0.00% 
PC 0 0 N/A 
NC 0 594 0.00% 
Table 75: L. fermentum's effect on biofilm maturation, near, day 1, P. aeruginosa 
Dose Species Biofilm  Percentage 
LF 4 125 3.20% 
PC 0 0 N/A 
NC 4 538 0.74% 
Table 76: L. fermentum's effect on biofilm maturation, near, day 3, P. aeruginosa 
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DISCUSSION 
 
This project was done to investigate the effectiveness of CNP and L. fermentum at reducing 
bacterial growth and biofilm formation of P. aeruginosa and S. aureus. These experiments 
looked at the effect of various aspects of CNP and L. fermentum, such as the dose, formulation, 
and potency. An XTT assay was also done to determine the viability of RAW 264.7 
macrophages treated with the various types of CNP. 
CNP 
 
Effect of Dose Response 
As seen in Tables 2-5, dextran-coated CNP at 500 µg/mL showed less bacterial growth and 
biofilm formation of P. aeruginosa. The higher concentrations of dextran-coated CNP were more 
effective at reducing the bacterial growth and biofilm formation. This is supported by another 
paper that found that dextran-coated CNP at higher concentrations was more effective at 
reducing P. aeruginosa bacterial growth than dextran-coated CNP at lower concentrations (10:1 
vs. 5:1 bacterial solution:CeO2 nanoparticles) [38]. A higher concentration of CNP correlates to a 
stronger dose, which has a higher amount of CNP available to prevent the growth of the bacteria 
than the amount present in the lower concentrations.  
50/50 CNP at 10 µg/mL seemed to have the most success at reducing bacterial growth and 
biofilm formation of the 50/50 CNP concentrations as seen in Tables 7-10. This finding is 
contrary to what was hypothesized. It was expected that higher concentrations would perform 
better. The equal amounts of Ce3+ and Ce4+ may work better at lower concentrations because 
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there is enough of a balance between the two valence states during the redox reactions. 50/50 
CNP may also demonstrate clumping at the higher concentrations, which further explains why 
the lower concentrations work better. Since the dextran-coated CNP is also a 50/50 valence ratio, 
these results also show that the dextran coating may have an effect on reducing the amount of 
clumping of the CNP and allowing the higher concentrations to penetrate the bacterial cells by 
keeping the particle size small. The prevention of clumping also allows the CNP to remain in 
solution [32], which aids in the delivery of CNP to its target. There was a significant increase in 
bacterial growth and biofilm formation from day 1 to day 3 with the 50/50 CNP at 20 µg/mL, as 
seen in Table 11. This may be due to the bacteria overcoming the initial effects of the CNP and 
growing by day 3. Little to no studies measured the antibacterial effects of CNP as far as three 
days, These results show that initial positive effects of CNP may only be short-term and more 
studies are required to determine why the effects may not be long-lasting and how to make the 
beneficial effects more long-term.  
For the 70/30 CNP, the 800 µg/mL group worked best at reducing bacterial growth and biofilm 
formation of P. aeruginosa, as seen in Tables 12-15. A higher proportion of Ce4+ has been 
shown to display catalase mimetic behavior [39]. One study showed that catalase activity 
protects biofilm by not allowing hydrogen peroxide to damage the biofilm [40]. However, these 
results contradict that conclusion. The high concentration of the 70/30 CNP may explain why it 
has a more inhibitory effect on the growth of P. aeruginosa biofilm.  
Effect of CNP formulation 
50/50 CNP at 10 µg/mL was more effective at reducing biofilm formation and bacterial growth 
than dextran-coated CNP at the same dose, as seen in Tables 21 and 22. This further enforces the 
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effectiveness of 50/50 CNP at 10 µg/mL at reducing infection as explained in the previous 
section. The dextran coated CNP at this concentration may not have been as effective at reducing 
infection due to dextran being a sugar. The coating may have been feeding the bacterial cells, 
rather than preventing their growth. Dextran-coated CNP at 500 µg/mL worked better at 
reducing biofilm formation and bacterial growth of P. aeruginosa than 70/30 CNP at the same 
dose, as seen in Tables 35 and 36. This result may be attributed to the dextran coating. The 
dextran coating may be preventing clumping, especially at this high concentration, which allows 
the CNP to remain dissolved in solution.   
CNP Potency 
As seen in Table 41, dextran-coated CNP at the 10 µg/mL concentration showed less bacterial 
growth and biofilm formation the further you moved away from the disk. This demonstrates a 
different in potency of this type of CNP. The CNP was significantly less potent close to the disk 
and became more potent further away. This may be due to the dextran coating feeding the 
bacteria closer to the interface and more of the CNP being uncoated as it moves farther away 
from the interface and actually reducing bacterial growth. The other groups of CNP showed a 
similar amount of bacterial growth and biofilm formation near the interface and far from the 
interface. This shows that the other groups have uniform potency and work just as well far from 
the disk as they do close to it.  
Effects of CNP on reducing biofilm maturation 
As seen in Table 50, 50/50 CNP at 20 µg/mL and 800 µg/mL had more species than biofilm near 
the disk interface. This was also observed with 70/30 CNP at 20 µg/mL and 800 µg/mL, as seen 
in Table 51. As seen in Table 52, 70/30 CNP at 100 µg/mL and 800 µg/mL had no biofilm, only 
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species. These treatment groups demonstrate that they may slow the progression of biofilm 
formation. This is a positive development because biofilm is significantly more difficult to 
eradicate than the bacterial species on their own. Preventing bacterial cells from forming biofilm 
makes it more likely that the infection can be eradicated. 
XTT Study 
The XTT assay was performed to determine the cell’s viability after being grown with the 
various groups of CNP. As seen in Tables 53 and 55, dextran-coated CNP and 70/30 CNP at 800 
µg/mL for both groups demonstrated cytotoxicity on the macrophages. 50/50 CNP at 500 µg/mL 
and 800 µg/mL also showed cytotoxicity, as seen in Table 57. On day 3, there was less cell 
viability. The only groups that showed cell proliferation on day 3 were 1 µg/mL dextran-coated 
CNP, 1, 10, and 20 µg/mL 70/30 CNP, as seen in Tables 54 and 56. This may be due to the 
bacteria not being able to grow well after being left in the CNP solutions. The low concentrations 
of CNP may not have been toxic to the macrophages because there was still enough media to 
support the growth of the macrophages. The CNP concentrations that were not toxic to the 
macrophages can be further studied because this assay shows they don’t have a negative effect 
on the growth of human macrophage cells. The high concentrations of treatment were probably 
not able to facilitate growth of the macrophages because there was too little media present for the 
macrophages to grow.  
Although these experimental groups didn’t work as well as the positive control, these results 
demonstrate that 50/50 CNP at 10 µg/mL may be effective at reducing P. aeruginosa infection, 
while not being toxic to macrophages. 
Beneficial Bacteria 
Effect of dose response 
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L. fermentum didn’t have much of an effect at reducing bacterial growth and biofilm formation 
of S. aureus. This is in contrast to a paper that found that secreted L. fermentum products 
inhibited S. aureus implant infections [41]. However, results of in vitro and in vivo studies may 
differ, which explains the discrepancy. The data did show significantly less infection with the P. 
aeruginosa on days 1 and 3 when the L. fermentum was compared to the negative control, as 
seen in Tables 64-67. This shows that a compound in the L. fermentum cell-free supernatant is 
having an effect on the P. aeruginosa and is reducing the bacterial growth and amount of 
biofilm. Bacteria of the Lactobacillus genus produce a multitude of substances, including 
reactive oxygen species and exopolysaccharides. The exopolysaccharides, in particular, have 
been shown to decrease the biofilm of both Gram-positive and Gram-negative bacterial species 
[42].  
LF Potency 
L. fermentum displayed a difference in infection totals between near and far on days 1 and 3 for 
S. aureus, as seen in Tables 69 and 70. There was less bacterial growth and biofilm formation 
close to the disk interface than far from it. This shows that L. fermentum’s potency decreases the 
farther it gets from the source. The substances in the L. fermentum supernatant may be less 
effective the farther they are from the source. There was also a difference in infection total on 
day 1 for P. aeruginosa, as seen in Table 71. However, there was also a difference in potency of 
the negative control, so this trial may not be accurate.  
Effects of LF on reducing biofilm maturation 
The L. fermentum supernatant didn’t have any effect on reducing the amount of biofilm when 
compared to the amount of species. This may be due to techniques employed in these 
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experiments to test the reduction of biofilm. Other culturing techniques or using L. fermentum 
itself may have produced more favorable results.  
 
The CNP and L. fermentum treatments showed little to no effect on S. aureus. S. aureus is one of 
the main bacteria involved in orthopedic implant infections [43]. This lack of results can be 
attributed to a few different causes. One paper discusses the effect of L. fermentum on S. aureus. 
The paper found that when S. aureus and P. aeruginosa were cultured together with L. 
fermentum there was a lack of biofilm formation [44]. The experiments ran for this thesis did not 
use L. fermentum bacteria itself to test its effect on S. aureus. Another technique this paper 
employed was the use of L. fermentum supernatant, which was also employed in these 
experiments done for this thesis. However, this paper investigated the depth of S. aureus biofilm 
and found that it was thinner than biofilm formed in the absence of L. fermentum supernatant 
[44]. In the experiments for this thesis, only the presence or absence of biofilm was tested. These 
limitations may explain why it seems that there was no effect by these treatments on the 
formation of biofilm by S. aureus.  
Troubleshooting played a major role in this project. Multiple trials had to be conducted to 
determine the correct type and dose of antibiotic, the correct volume of bacteria to plate to 
develop a lawn of bacteria, and other factors that were necessary to know before starting the 
experimental trials. There were also issues with the incubator used that led to drying out of the 
plates.  
There are many questions to investigate in further experiments. For example, there are many 
species of beneficial bacteria. However, in this experiment, only one was tested. Future 
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experiments can test other species of beneficial bacteria, such as L. plantarum and L. 
acidophilus, to see if they lead to more favorable results in decreasing bacterial infection. The 
Kirby-Bauer disk diffusion method was the main technique used for testing the effectiveness of 
the compounds. However, other papers have employed other methods, such as culturing the 
treatment solutions with the bacterial solutions and incubating them [38], that may be more 
effective. In the literature, orthopedic implant infections can be described as polymicrobial, in 
which infections are made up of more than one type of bacteria. Creating bacterial co-cultures 
and testing various treatments on them rather than on lawns of one type of bacteria is more 
representative of an actual infection. Therefore, the results would be more useful in future 
clinical trials and in vivo studies. These experiments were performed in triplicate. In the future, a 
larger sample size can be used to generate more reliable data. CNP has a tendency to clump 
together, especially at higher concentrations. In this experiment, dextran was used as a coating to 
prevent clumping. However, other coatings, such as polyacrylic acid [38], are also available. 
Other coatings may be more effective at reducing the biofilm and growth of the bacteria 
specifically involved in orthopedic implant infections. Another limitation of this study was that 
pH was not considered. As stated in the introduction, CNP can behave differently in different pH 
conditions. In future experiments, this can be addressed. In the future, experiments aimed at 
investigating these substances on metal disks or surfaces will be performed to get results that can 
be better applied to actual implant surfaces. Macrophages were used in this study because they 
are immune cells and are involved in fighting infections, such as orthopedic implant infections. 
However, orthopedic implants affect more than just macrophages. In the future, it would be 
beneficial to measure the cytotoxicity of various treatments on other types of cells, such as 
osteoblasts to determine how the treatments affect the whole body, not just one cell type.  
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CONCLUSION 
 
In conclusion, the most effective experimental group was 50/50 at 10 µg/mL because it 
reduced bacterial growth and biofilm formation, but wasn’t toxic to the macrophages. Some of 
the high CNP concentrations, such as 70/30 CNP at 800 µg/mL also showed a reduction in 
bacterial growth and biofilm formation. However, they also showed cytotoxicity on the 
macrophages. L. fermentum had some success with P. aeruginosa, but not with S. aureus. 50/50 
at 10 µg/mL should be further investigated, especially in experiments that better reflect 
orthopedic implant infections. These results add to the growing knowledge of CNP and its uses 
in medicine.  
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